Management of Advanced Oral Cancers - Dr Pallavi Kaul

Value of the Information & Strength of the Argument

The presentation provides valuable information for clinicians, especially in India, by synthesizing evidence from landmark trials and guidelines. It offers practical insights into surgical reconstruction techniques adapted to resource-limited settings. The argumentation is generally solid, with references to key studies such as the JAMA 2016 analysis, Bernier and Cooper trials, Patal trial, and EXTREME trial. However, some claims lack specific citations, and the presentation is an expert opinion rather than a systematic review. The speaker’s perspective from working in Australia and India adds practical value, but the argumentation could be strengthened by more detailed discussion of evidence limitations.

Scientific Rigor, Source Quality, Title Accuracy

The presentation demonstrates scientific rigor by referencing major trials and guidelines (NCCN, AJCC). The sources cited are appropriate and relevant, though not all are explicitly named in the transcript. The title accurately reflects the content, which is focused on management strategies. The speaker’s expertise is evident, but the lack of formal citations in the slides and the reliance on personal experience may reduce the overall rigor. The content is up-to-date, mentioning recent concepts like response-adapted surgery and immunotherapy. No comments were provided for analysis.

The title accurately reflects the content, which focuses on the management of advanced oral cancers.

7/10

The presentation is based on established guidelines (NCCN, AJCC) and landmark trials (Bernier, Cooper, EXTREME, etc.), but it is an expert opinion without detailed methodology or peer review, and some claims lack specific citations.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 02:00Introduction and overview of the global and Indian burden of oral cancer.
• 10:00Discussion of the four clinical settings of advanced oral cancer.
• 20:00Evidence for surgery as primary treatment, including the JAMA 2016 study.
• 30:00Adjuvant therapy trials (Bernier and Cooper) and NCCN recommendations.
• 40:00Reconstruction challenges and Indian solutions (pectoralis major flap, etc.).
• 50:00Borderline resectable disease and the Patal trial on neoadjuvant chemotherapy.
• 1:00:00Unresectable disease management: chemotherapy, targeted therapy, and immunotherapy.

• NCCN Guidelines for Head and Neck Cancers — Referenced for management guidelines in advanced oral cancer.
• AJCC Cancer Staging Manual, 9th Edition — Referenced for staging of oral cancers.
• Bernier et al. (2004) - Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer (EORTC 22931) — Landmark trial on adjuvant chemoradiotherapy.
• Cooper et al. (2004) - Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck (RTOG 9501) — Landmark trial on adjuvant chemoradiotherapy.
• Patal et al. (2014) - Neoadjuvant chemotherapy in technically unresectable oral cavity cancers — Key study on borderline resectable oral cancers.
• Vermorken et al. (2008) - Platinum-based chemotherapy plus cetuximab in head and neck cancer (EXTREME trial) — Landmark trial for cetuximab in recurrent/metastatic disease.
• Marta et al. (2015) - Meta-analysis of neoadjuvant chemotherapy in oral cavity cancer — Referenced for meta-analysis on neoadjuvant chemotherapy.

• NCCN Guidelines — Consistent with standard management recommendations.
• Bernier and Cooper trials — Support the use of adjuvant chemoradiotherapy in high-risk resectable disease.

• Licitra et al. (2003) - Neoadjuvant chemotherapy in resectable oral cavity cancer